Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Compounded Pyrimethamine: 'Personalized Medicine' Or 'Unapproved Drug'?

Executive Summary

Responding to the Express Scripts' deal to promote use of a compounded alternative to its drug, Turing says physicians shouldn't prescribe the compound, since it is an unapproved and unsafe drug. But the compounder, Imprimis, says each prescription is custom-made, making it a "personalized medicine."

You may also be interested in...



Compounding For Lower Prices Not PBMs’ New ‘Game Plan,’ Lawmakers Told

Pharmacy benefit manager trade group chief Mark Merritt says PBMs are not poised to broadly promote compounded drugs as cheaper alternatives to off-patent drugs with no generic competition.

Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs

Pharmacy benefit manager's anti-Daraprim effort signals new direction in pricing battles, but the strategy can only be used in limited circumstances.

FDA Steps Into Makena Pricing Dispute In The Name Of "Access"

FDA is citing patient access as the reason behind its unusual decision to insert itself in the middle of a pricing debate involving KV Pharmaceuticals’ pre-term delivery drug Makena.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel